《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2015年 > 6期

口服降糖药治疗血糖控制不佳的2型糖尿病患者联用艾塞那肽安全性和疗效观察

来自:中国糖尿病杂志  编辑:顾丽萍 张颖 顾鸣宇 严率 吴艺捷|点击数:|2015-06-17

  糖尿病临床研究

  [摘要] 目的 观察艾塞那肽治疗口服降糖药(OADs)治疗血糖控制欠佳T2DM患者的临床疗效及安全性。 方法 对40例OADs治疗血糖控制欠佳且BMI>23 kg/m2的T2DM患者加用艾塞那肽治疗12周,测定治疗前后相关指标;稳态模型评估胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)。结果 加用艾塞那肽治疗12周后FPG、2 hPG、HbA1c、HOMA-IR、TG较治疗后下降[FPG(8.77±1.92)vs (7.49±1.14) mmol/L;2 hPG(16.55±3.20)vs(14.69±1.50)mmol/L;HbA1c(8.91±1.37)% vs (7.94±0.90)% ;HOMA-IR(1.44±0.41)vs(1.24±0.25); TG(2.21±1.34)vs(1.59±0.51)mmol/L] (P<0.01);2 hIns及HOMA-β较治疗前增加[(6.10±0.46)vs(5.96±0.65)pmol/L;(4.01±0.32)vs (3.81±0.54)](P<0.05或P<0.01)。所有病例均无严重低血糖事件发生。 结论 使用OADs治疗欠佳的T2DM患者加用艾塞那肽可降低血糖、BMI及TG,同时改善胰岛β细胞功能和IR,且安全性较好。

  [关键词]糖尿病,2型;胰升血糖素样肽-1;艾塞那肽

  【Abstract】 Objective To evaluate the efficacy and safety of oral hypoglycemic drugs (OADs) in combination with exenatide in poor glycemic control patients with type 2 diabetes mellitus (T2DM). Methods 40 patients, with poor glycemic control and body mass index (BMI)>23 kg/m2 were given exenatide injection for 12 weeks. Indicators were measured before and after the treatment. Insulin resistance index (HOMA-IR) and Islet β-cell function index (HOMA-β) were calculated. Results: The levels of FPG(7.49±1.14)mmol/L, 2 hPG(14.69±1.50)mmol/L, HbA1c(7.94±0.90)% declined significantly after the treatment than before[(8.77±1.92)mmol/L, (16.55±3.24)mmol/L, (8.91±1.37)%, respectively] (all P<0.01). The level of postprandial 2 hIns (6.10±0.46)pmol/L increased significantly than before (5.96±0.65)pmol/L(P<0.05). After treatment, HOMA-β index (4.01±0.32) increased than before (3.81±0.54) (P<0.01), with HOMA-IR to descend [(1.44±0.41) vs (1.24±0.25)] (P<0.01). Body weight (87.7±10.7)kg and BMI (30.34±2.91)kg/m2 dropped to (85.0±9.8)kg and (29.41±2.59)kg/m2 (P<0.01). Also, TG declined [(2.21±1.34) vs (1.59±0.51)mmol/L] (P<0.01). No significant differences in blood pressure, lipids, liver and kidney functions were observed after the treatment (P>0.05). There was no severe hypoglycemic episode. Conclusion Exenatide injection decreased the levels of FPG, 2hPG, HbA1c, BMI and TG significantly in poor control T2DM treated with oral hypoglycemic agents with better safety. It can also significantly improve islet β cell function and decrease insulin resistance..

  [Key words] Diabetes mellitus,type 2;Glucagon like peptide-1;Exenatide

上一篇:地特胰岛素联合利拉鲁肽治疗血糖控制不佳2型糖尿病患者的临床观察 下一篇:胰岛素自身抗体影响胰岛素测定及作用的临床及实验分析二例报道

相关阅读

    暂时没有相关文章